Please assess the completion status of the following clinical trial:

Trial Title: Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female patients ≥18 years of age who are HLA-A\*02+ (performed during screening locally or centrally, or based on documented historic test results)~* Histologically confirmed incurable or metastatic solid tumors that are HPV16+ (performed during screening locally or centrally, or based on documented historic test results)~* Cancer must have progressed after at least 1 available standard therapy for incurable disease, or the patient is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exist~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1~* At least 1 measurable lesion according to RECIST 1.1~* Must have a lesion that can be biopsied with acceptable clinical risk and agree to have a fresh biopsy at Baseline and on Cycle 2 Day 8 (+/- 3 days)~* Patients must agree to venous access for the leukapheresis and be willing to have a central line inserted if venous access is an issue~* Adequate organ function and bone marrow reserve performed within 14 days prior to the leukapheresis~Exclusion Criteria:~* Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to leukapheresis. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis~* Systemic treatment with either corticosteroids (\>10 mg of prednisone or the equivalent per day) or other immunosuppressive medications within 14 days prior to leukapheresis~* Patients treated with non-corticosteroid based immunosuppressive agents within the last 6 months may not be eligible and should be discussed with the Sponsor~* Patients with active, known, or suspected autoimmune disease may not be eligible and should be discussed with the Sponsor~* Patients with \>Grade 1 AEs related to previous treatment with anticancer or investigational therapy that do not resolve at least 2 weeks prior to leukapheresis, except neuropathy, ototoxicity, mucositis, fatigue, alopecia, or endocrine disorders managed with hormone replacement~* Known active hepatitis B or hepatitis C, or active mycobacterium tuberculosis infection~* History of any Grade 3 immune-related AE (irAE) from prior immunotherapy~* Has known active central nervous system metastases~* History of interstitial lung disease requiring steroids~* Major surgery within 2 weeks of leukapheresis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 Monotherapy Dose Escalation Phase (Type: EXPERIMENTAL): In Part 1, SQZ-PBMC-HPV as a monotherapy is administered on Day 1 of every 3 week cycles for up to a year. In Cohort 3 (double-priming), SQZ-PBMC-HPV is also administered on Day 2 of Cycle 1. There are at least 3 groups (Cohorts) in this Phase as follows:~* Cohort 1: specified dose SQZ-PBMC-HPV~* Cohort 2: specified dose SQZ-PBMC-HPV~* Cohort 3: specified dose SQZ-PBMC-HPV double-priming
- Part 2 Combination Safety Phase (Type: EXPERIMENTAL): In Part 2, SQZ-PBMC-HPV in combination with immune checkpoint inhibitors (1) atezolizumab, (2) ipilimumab, (3) nivolumab, or (4) nivolumab and ipilimumab, is administered every 3 weeks for up to a year except atezolizumab may be given up to 2 years; and ipilimumab will be administered four times (in a timeframe less than a year) if safety allows. There are 4 groups (Cohorts) in this Phase as follows:~* Cohort 4: SQZ-PBMC-HPV RP2D (Recommended Phase 2 Dose) plus atezolizumab~* Cohort 5: SQZ-PBMC-HPV RP2D plus ipilimumab~* Cohort 6: SQZ-PBMC-HPV RP2D plus nivolumab~* Cohort 7: SQZ-PBMC-HPV RP2D plus nivolumab and ipilimumab
- Part 3 Monotherapy Dose Expansion Phase (Type: EXPERIMENTAL): In Part 3, SQZ-PBMC-HPV is administered at the RP2D to patients enrolled in HPV16+ cancer-type specific cohorts. There are 4 groups (Cohorts) in this Phase as follows:~* Cohort 8: SQZ-PBMC-HPV RP2D in HPV16+ head and neck cancer patients~* Cohort 9: SQZ-PBMC-HPV RP2D in HPV16+ cervical cancer patients~* Cohort 10: SQZ-PBMC-HPV RP2D in HPV16+ anal cancer patients~* Cohort 11: SQZ-PBMC-HPV RP2D in other HPV16+ cancer patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete